University of California, San Francisco
ucsf.eduTotal trials
2,119
Active
453
Phase 3
89
Total enrollment
11,695,067
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 187 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Azithromycin | — | — | — | — | 21 | ||
| Guselkumab | — | — | — | — | — | 3 | |
| Normal saline | — | — | 5 | ||||
| Dupilumab | — | — | — | — | — | 4 | |
| Infliximab | — | — | — | 3 | |||
| Upadacitinib | — | — | — | — | — | 2 | |
| Sodium chloride | — | — | — | — | — | 2 | |
| Deucravacitinib | — | — | — | — | — | 2 | |
| Cyclosporine | — | — | — | 4 | |||
| Ocrelizumab | — | — | — | — | 3 | ||
| 5-fluorouracil | — | — | 5 | ||||
| Amoxicillin | — | — | — | — | 4 | ||
| Azithromycin for Oral Suspension | — | — | — | — | — | 3 | |
| Trimethoprim-Sulfamethoxazole | — | — | — | — | 3 | ||
| Phenylephrine | — | — | — | — | 3 | ||
| Tildrakizumab | — | — | — | — | — | 2 | |
| Albuterol | — | — | — | — | 2 | ||
| Ustekinumab | — | — | — | — | — | 2 | |
| Secukinumab | — | — | — | — | — | 2 | |
| Ruxolitinib | — | — | — | — | 2 | ||
| Losartan | — | — | — | — | 2 | ||
| Norepinephrine | — | — | — | — | — | 2 | |
| Oral Methamphetamine | — | — | — | — | — | 2 | |
| Lemborexant | — | — | — | — | — | 2 | |
| Mirabegron | — | — | — | — | — | 2 | |
| Doxycycline 40 MG | — | — | — | — | — | 1 | |
| Doxycycline 200 MG | — | — | — | — | — | 1 | |
| Atropine 1% | — | — | — | — | — | 1 | |
| Study Drug Placebo | — | — | — | — | — | 1 | |
| Vaseline | — | — | — | — | — | 1 | |
| Magnesium sulfate administration | — | — | — | — | — | 1 | |
| Triamcinolone | — | — | — | — | — | 1 | |
| Calcipotriene | — | — | — | — | — | 1 | |
| Tapinarof | — | — | — | — | — | 1 | |
| Crisaborole | — | — | — | — | — | 1 | |
| Adalimumab | — | — | — | — | — | 1 | |
| Certolizumab | — | — | — | — | — | 1 | |
| Ixekizumab | — | — | — | — | — | 1 | |
| Apremilast | — | — | — | — | — | 1 | |
| Risankizumab | — | — | — | — | — | 1 |
147 more active programs hidden
Next readouts
- 2023-01-31
- 2024-08-01
- 2024-11-01
- 2024-12-31
- 2025-01-16
- 2025-01-30
- 2025-04-04
- 2025-07-11
- 2025-12-31
- 2025-12-31
Top conditions
- HIV62
- HIV Infections56
- Prostate Cancer44
- Breast Cancer42
- Depression40
- Healthy36
- HIV/AIDS32
- Asthma31
Frequently asked questions about University of California, San Francisco
- How many clinical trials does University of California, San Francisco have on ClinicalTrials.gov?
- University of California, San Francisco is listed as the lead sponsor on 2,119 clinical trials in ClinicalTrials.gov, 453 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of California, San Francisco's trials are in Phase 3?
- 89 of University of California, San Francisco's trials are in Phase 3, spread across 187 active drug programs.
- What therapeutic areas does University of California, San Francisco focus on?
- University of California, San Francisco's most-studied conditions on ClinicalTrials.gov are HIV, HIV Infections, Prostate Cancer, Breast Cancer, Depression.
- When are University of California, San Francisco's next clinical trial readouts?
- University of California, San Francisco has 10 upcoming primary-completion readouts tracked here; the soonest is “Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery”, expected around 2023-01-31.